You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMoclobemide
Accession NumberDB01171  (APRD00603)
TypeSmall Molecule
GroupsApproved
DescriptionA reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder.
Structure
Thumb
Synonyms
4-Chlor-N-(2-morpholinoethyl)benzamid
4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide
4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide
Aurorix
Moclaime
Moclamide
Moclamine
Moclobemid
Moclobemida
Moclobemide
Moclobemidum
p-Chloro-N-(2-morpholinoethyl)benzamide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-moclobemide Tablets 150mgtablet150 mgoralDominion Pharmacal2001-02-15Not applicableCanada
Dom-moclobemide Tablets 300mgtablet300 mgoralDominion Pharmacal2001-02-15Not applicableCanada
Manerixtablet150 mgoralValeant Canada Lp Valeant Canada S.E.C.1992-12-31Not applicableCanada
Manerixtablet300 mgoralValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada
Manerix Tab 100mgtablet100 mgoralHoffmann La Roche Limited1992-12-311997-12-04Canada
Moclobemide-100tablet100 mgoralPro Doc Limitee1998-06-022009-07-23Canada
Moclobemide-150tablet150 mgoralPro Doc Limitee1998-06-022009-07-23Canada
Nu-moclobemidetablet100 mgoralNu Pharm Inc1998-07-292012-09-04Canada
Nu-moclobemidetablet150 mgoralNu Pharm Inc1998-07-282012-09-04Canada
PMS-moclobemidetablet300 mgoralPharmascience Inc2001-01-08Not applicableCanada
PMS-moclobemidetablet150 mgoralPharmascience Inc2001-01-08Not applicableCanada
Ratio-moclobemide - Tab 150mgtablet150 mgoralRatiopharm Inc Division Of Teva Canada Limited1997-10-012006-08-04Canada
Ratio-moclobemide - Tab 300mgtablet300 mgoralRatiopharm Inc Division Of Teva Canada Limited1999-07-122006-08-04Canada
Riva-moclobemide 150mg Tabletstablet150 mgoralLaboratoire Riva Inc1999-08-302003-07-28Canada
Riva-moclobemide 300mg Tabletstablet300 mgoralLaboratoire Riva Inc1999-08-302003-07-28Canada
Teva-moclobemidetablet100 mgoralTeva Canada Limited1999-05-20Not applicableCanada
Teva-moclobemidetablet150 mgoralTeva Canada Limited1999-05-20Not applicableCanada
Teva-moclobemidetablet300 mgoralTeva Canada Limited1999-05-20Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-moclobemidetablet100 mgoralApotex Inc1997-09-18Not applicableCanada
Apo-moclobemidetablet150 mgoralApotex Inc1997-09-18Not applicableCanada
Apo-moclobemidetablet300 mgoralApotex Inc1999-07-14Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AurorixNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIPJ0Y7AZB63
CAS number71320-77-9
WeightAverage: 268.739
Monoisotopic: 268.097855505
Chemical FormulaC13H17ClN2O2
InChI KeyInChIKey=YHXISWVBGDMDLQ-UHFFFAOYSA-N
InChI
InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)
IUPAC Name
4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide
SMILES
ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 4-halobenzoic acids and derivatives. These are benzoic acids or derivatives carrying a halogen atom at the 4-position of the benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct Parent4-halobenzoic acids and derivatives
Alternative Parents
Substituents
  • 4-halobenzoic acid or derivatives
  • Benzamide
  • Benzoyl
  • Halobenzene
  • Chlorobenzene
  • Oxazinane
  • Morpholine
  • Aryl halide
  • Aryl chloride
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of depression.
PharmacodynamicsMoclobemide belongs to a class of MAOI antidepressants known as reversible inhibitors of monoamine oxidase type-A (RIMAs). The primary role of monoamine oxidase MAO lies in the metabolism of and regulation of the levels of monoamines (serotonin, norepinephrine, and dopamine). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms. RIMAs demonstrate transient inhibition of the substrate binding site of MAO-A as well as competitive displacement from this site by bioamines. The RIMAs are distinguished from the older monoamine oxidase inhibitors (MAOIs) by their selectivity and reversibility.
Mechanism of actionThe mechanism of action of moclobemide involves the selective, reversible inhibition of MAO-A. This inhibition leads to a decrease in the metabolism and destruction of monoamines in the neurotransmitters. This results in an increase in the monoamines, relieving depressive symptoms.
Related Articles
AbsorptionWell absorbed from the gastrointestinal tract (> 95%). The presence of food reduces the rate but not the extent of absorption. Hepatic first pass metabolism reduces bioavailability to 45-70% following administration of a single dose, but increases to 80% with multiple dosing as a result of saturation of the first pass effect. Peak plasma concentrations are reached within 1 - 2 hours following oral administration.
Volume of distributionNot Available
Protein bindingApproximately 50% (primarily to albumin)
Metabolism

Moclobemide is almost completely metabolized in the liver by Cytochrome P450 2C19 and 2D6.

Route of eliminationNot Available
Half life1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted
ClearanceNot Available
ToxicityLD50 (mouse) is 730mg/kg and LD50 (rat) is 1,300mg/kg. Signs of toxicity include hypertension, drowsiness, dizziness, confusion, tremors, headache, agitation, muscle rigidity and seizures.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9838
Blood Brain Barrier+0.9691
Caco-2 permeable-0.5602
P-glycoprotein substrateSubstrate0.6652
P-glycoprotein inhibitor IInhibitor0.6892
P-glycoprotein inhibitor IINon-inhibitor0.8637
Renal organic cation transporterNon-inhibitor0.5691
CYP450 2C9 substrateNon-substrate0.8538
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5723
CYP450 1A2 substrateNon-inhibitor0.9138
CYP450 2C9 inhibitorNon-inhibitor0.8989
CYP450 2D6 inhibitorNon-inhibitor0.8081
CYP450 2C19 inhibitorInhibitor0.8024
CYP450 3A4 inhibitorNon-inhibitor0.9384
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5956
Ames testNon AMES toxic0.6867
CarcinogenicityNon-carcinogens0.8727
BiodegradationNot ready biodegradable0.9844
Rat acute toxicity2.6098 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7135
hERG inhibition (predictor II)Inhibitor0.5646
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral100 mg
Tabletoral150 mg
Tabletoral300 mg
Prices
Unit descriptionCostUnit
Manerix 300 mg Tablet1.34USD tablet
Apo-Moclobemide 300 mg Tablet0.75USD tablet
Novo-Moclobemide 300 mg Tablet0.75USD tablet
Pms-Moclobemide 300 mg Tablet0.75USD tablet
Manerix 150 mg Tablet0.68USD tablet
Apo-Moclobemide 150 mg Tablet0.38USD tablet
Novo-Moclobemide 150 mg Tablet0.38USD tablet
Pms-Moclobemide 150 mg Tablet0.38USD tablet
Apo-Moclobemide 100 mg Tablet0.26USD tablet
Novo-Moclobemide 100 mg Tablet0.26USD tablet
Nu-Moclobemide 100 mg Tablet0.26USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP1.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.12 mg/mLALOGPS
logP1.56ALOGPS
logP1.45ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)14.73ChemAxon
pKa (Strongest Basic)6.02ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.57 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity71.93 m3·mol-1ChemAxon
Polarizability28.28 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0udi-2900000000-c3230d46878446405991View in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN06AG02
AHFS Codes
  • 28:16.04.12
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineMoclobemide may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineMoclobemide may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Moclobemide.
AbirateroneThe metabolism of Moclobemide can be decreased when combined with Abiraterone.
AcarboseMoclobemide may increase the hypoglycemic activities of Acarbose.
AcebutololMoclobemide may increase the hypotensive activities of Acebutolol.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Moclobemide.
AcepromazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Aceprometazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Acetophenazine.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Moclobemide.
AlbiglutideMoclobemide may increase the hypoglycemic activities of Albiglutide.
AliskirenMoclobemide may increase the hypotensive activities of Aliskiren.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Moclobemide.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Moclobemide.
AlogliptinMoclobemide may increase the hypoglycemic activities of Alogliptin.
AlprenololMoclobemide may increase the hypotensive activities of Alprenolol.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Moclobemide.
AmbrisentanMoclobemide may increase the hypotensive activities of Ambrisentan.
AmineptineMoclobemide may increase the serotonergic activities of Amineptine.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Moclobemide.
AmiodaroneThe metabolism of Moclobemide can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Amisulpride.
AmitriptylineMoclobemide may increase the serotonergic activities of Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Moclobemide.
AmlodipineMoclobemide may increase the hypotensive activities of Amlodipine.
AmoxapineMoclobemide may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Moclobemide.
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Moclobemide.
AmperozideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Amperozide.
AmphetamineMoclobemide may increase the hypertensive activities of Amphetamine.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Moclobemide.
ApixabanThe metabolism of Apixaban can be decreased when combined with Moclobemide.
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Moclobemide.
ApraclonidineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Apraclonidine.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Moclobemide.
ArbutamineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Arbutamine.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Moclobemide.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Moclobemide.
ArmodafinilThe metabolism of Moclobemide can be decreased when combined with Armodafinil.
ArtemetherThe metabolism of Moclobemide can be decreased when combined with Artemether.
AsenapineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Asenapine.
AtenololMoclobemide may increase the hypotensive activities of Atenolol.
AtomoxetineMoclobemide may increase the central neurotoxic activities of Atomoxetine.
AtomoxetineThe metabolism of Moclobemide can be decreased when combined with Atomoxetine.
AtropineMoclobemide may increase the hypertensive activities of Atropine.
AxitinibThe metabolism of Axitinib can be decreased when combined with Moclobemide.
AzaperoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Azaperone.
AzelastineThe metabolism of Azelastine can be decreased when combined with Moclobemide.
BambuterolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Bambuterol.
BenazeprilMoclobemide may increase the hypotensive activities of Benazepril.
BendroflumethiazideMoclobemide may increase the hypotensive activities of Bendroflumethiazide.
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Moclobemide.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Moclobemide.
BenzphetamineMoclobemide may increase the hypertensive activities of Benzphetamine.
BepridilMoclobemide may increase the hypotensive activities of Bepridil.
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Moclobemide.
BetaxololMoclobemide may increase the hypotensive activities of Betaxolol.
BetaxololThe metabolism of Moclobemide can be decreased when combined with Betaxolol.
BethanidineMoclobemide may increase the hypotensive activities of Bethanidine.
BezafibrateThe risk or severity of adverse effects can be increased when Moclobemide is combined with Bezafibrate.
BifeprunoxThe risk or severity of adverse effects can be increased when Moclobemide is combined with Bifeprunox.
BimatoprostMoclobemide may increase the hypotensive activities of Bimatoprost.
BisoprololMoclobemide may increase the hypotensive activities of Bisoprolol.
BortezomibThe metabolism of Moclobemide can be decreased when combined with Bortezomib.
BosentanMoclobemide may increase the hypotensive activities of Bosentan.
BretyliumMoclobemide may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Moclobemide is combined with Brexpiprazole.
BrimonidineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Brimonidine.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Moclobemide.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Moclobemide.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Moclobemide.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Moclobemide.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Moclobemide.
BupranololMoclobemide may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Moclobemide.
BupropionMoclobemide may increase the hypertensive activities of Bupropion.
BupropionThe metabolism of Moclobemide can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Moclobemide.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Moclobemide.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Moclobemide.
CanagliflozinMoclobemide may increase the hypoglycemic activities of Canagliflozin.
CandesartanMoclobemide may increase the hypotensive activities of Candesartan.
CandoxatrilMoclobemide may increase the hypotensive activities of Candoxatril.
CapecitabineThe metabolism of Moclobemide can be decreased when combined with Capecitabine.
CaptoprilMoclobemide may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Moclobemide.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Moclobemide.
CariprazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Cariprazine.
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Moclobemide.
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Moclobemide.
CarteololMoclobemide may increase the hypotensive activities of Carteolol.
CarvedilolMoclobemide may increase the hypotensive activities of Carvedilol.
CelecoxibThe metabolism of Moclobemide can be decreased when combined with Celecoxib.
CeliprololMoclobemide may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Moclobemide can be increased when it is combined with Ceritinib.
ChloramphenicolThe metabolism of Moclobemide can be decreased when combined with Chloramphenicol.
ChloroquineThe metabolism of Moclobemide can be decreased when combined with Chloroquine.
ChlorothiazideMoclobemide may increase the hypotensive activities of Chlorothiazide.
ChlorphentermineMoclobemide may increase the hypertensive activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Chlorpromazine.
ChlorpromazineThe metabolism of Moclobemide can be decreased when combined with Chlorpromazine.
ChlorpropamideMoclobemide may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Chlorprothixene.
ChlorthalidoneMoclobemide may increase the hypotensive activities of Chlorthalidone.
CholecalciferolThe metabolism of Moclobemide can be decreased when combined with Cholecalciferol.
CilazaprilMoclobemide may increase the hypotensive activities of Cilazapril.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Moclobemide.
CimetidineThe metabolism of Moclobemide can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Moclobemide can be decreased when combined with Cinacalcet.
CirazolineMoclobemide may increase the hypertensive activities of Cirazoline.
CisaprideThe metabolism of Cisapride can be decreased when combined with Moclobemide.
CitalopramMoclobemide may increase the serotonergic activities of Citalopram.
CitalopramThe metabolism of Moclobemide can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Moclobemide.
ClemastineMoclobemide may increase the anticholinergic activities of Clemastine.
ClemastineThe metabolism of Moclobemide can be decreased when combined with Clemastine.
ClenbuterolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Clenbuterol.
ClobazamThe metabolism of Moclobemide can be decreased when combined with Clobazam.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Moclobemide.
ClomipramineMoclobemide may increase the serotonergic activities of Clomipramine.
ClomipramineThe metabolism of Moclobemide can be decreased when combined with Clomipramine.
ClonidineMoclobemide may increase the hypotensive activities of Clonidine.
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Moclobemide.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Moclobemide.
ClotrimazoleThe metabolism of Moclobemide can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Clozapine.
ClozapineThe metabolism of Moclobemide can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Moclobemide can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Moclobemide can be decreased when combined with Cocaine.
CryptenamineMoclobemide may increase the hypotensive activities of Cryptenamine.
CyamemazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Cyamemazine.
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Moclobemide.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Moclobemide.
CyclosporineThe metabolism of Moclobemide can be decreased when combined with Cyclosporine.
CyclothiazideMoclobemide may increase the hypotensive activities of Cyclothiazide.
CyproheptadineMoclobemide may increase the anticholinergic activities of Cyproheptadine.
DabrafenibThe serum concentration of Moclobemide can be decreased when it is combined with Dabrafenib.
DapagliflozinMoclobemide may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Moclobemide is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Moclobemide.
DapoxetineMoclobemide may increase the serotonergic activities of Dapoxetine.
DapsoneThe metabolism of Dapsone can be decreased when combined with Moclobemide.
DarifenacinThe metabolism of Moclobemide can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Moclobemide can be increased when it is combined with Darunavir.
DebrisoquinMoclobemide may increase the hypotensive activities of Debrisoquin.
DelavirdineThe metabolism of Moclobemide can be decreased when combined with Delavirdine.
DeserpidineMoclobemide may increase the hypotensive activities of Deserpidine.
DesipramineMoclobemide may increase the serotonergic activities of Desipramine.
DesipramineThe metabolism of Moclobemide can be decreased when combined with Desipramine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Moclobemide.
DesvenlafaxineMoclobemide may increase the serotonergic activities of Desvenlafaxine.
DexmethylphenidateMoclobemide may increase the hypertensive activities of Dexmethylphenidate.
DextroamphetamineMoclobemide may increase the hypertensive activities of Dextroamphetamine.
DextromethorphanMoclobemide may increase the serotonergic activities of Dextromethorphan.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Moclobemide.
DiazepamThe metabolism of Diazepam can be decreased when combined with Moclobemide.
DiazoxideMoclobemide may increase the hypotensive activities of Diazoxide.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Moclobemide.
DiethylpropionMoclobemide may increase the hypertensive activities of Diethylpropion.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Moclobemide.
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Moclobemide.
DiltiazemMoclobemide may increase the hypotensive activities of Diltiazem.
DiphenhydramineThe metabolism of Moclobemide can be decreased when combined with Diphenhydramine.
DipivefrinThe risk or severity of adverse effects can be increased when Moclobemide is combined with Dipivefrin.
DisopyramideMoclobemide may increase the hypoglycemic activities of Disopyramide.
DobutamineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Dobutamine.
DolasetronDolasetron may increase the serotonergic activities of Moclobemide.
DomperidoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Domperidone.
DopamineThe metabolism of Dopamine can be decreased when combined with Moclobemide.
DorzolamideMoclobemide may increase the hypotensive activities of Dorzolamide.
DosulepinMoclobemide may increase the serotonergic activities of Dosulepin.
DoxapramMoclobemide may increase the hypertensive activities of Doxapram.
DoxazosinMoclobemide may increase the hypotensive activities of Doxazosin.
DoxepinMoclobemide may increase the serotonergic activities of Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Moclobemide.
DoxylamineMoclobemide may increase the anticholinergic activities of Doxylamine.
DronabinolThe metabolism of Dronabinol can be decreased when combined with Moclobemide.
DronedaroneThe metabolism of Moclobemide can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Droperidol.
DroxidopaThe risk or severity of adverse effects can be increased when Moclobemide is combined with Droxidopa.
DulaglutideMoclobemide may increase the hypoglycemic activities of Dulaglutide.
DuloxetineThe metabolism of Moclobemide can be decreased when combined with Duloxetine.
DuloxetineMoclobemide may increase the serotonergic activities of Duloxetine.
EfavirenzThe metabolism of Moclobemide can be decreased when combined with Efavirenz.
EfonidipineMoclobemide may increase the hypotensive activities of Efonidipine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Moclobemide.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Moclobemide.
EliglustatThe metabolism of Moclobemide can be decreased when combined with Eliglustat.
EmpagliflozinMoclobemide may increase the hypoglycemic activities of Empagliflozin.
EnalaprilMoclobemide may increase the hypotensive activities of Enalapril.
EnalaprilatMoclobemide may increase the hypotensive activities of Enalaprilat.
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Moclobemide.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Moclobemide.
EphedraThe risk or severity of adverse effects can be increased when Moclobemide is combined with Ephedra.
EpinephrineMoclobemide may increase the hypertensive activities of Epinephrine.
EpoprostenolMoclobemide may increase the hypotensive activities of Epoprostenol.
EprosartanMoclobemide may increase the hypotensive activities of Eprosartan.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Moclobemide.
ErgonovineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Moclobemide.
ErgotamineMoclobemide may increase the hypertensive activities of Ergotamine.
EscitalopramMoclobemide may increase the serotonergic activities of Escitalopram.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Moclobemide.
Eslicarbazepine acetateThe metabolism of Moclobemide can be decreased when combined with Eslicarbazepine acetate.
EsmirtazapineMoclobemide may increase the serotonergic activities of Esmirtazapine.
EsomeprazoleThe metabolism of Moclobemide can be decreased when combined with Esomeprazole.
EstradiolThe metabolism of Estradiol can be decreased when combined with Moclobemide.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Moclobemide.
EtoperidoneMoclobemide may increase the serotonergic activities of Etoperidone.
EtravirineThe metabolism of Etravirine can be decreased when combined with Moclobemide.
ExenatideMoclobemide may increase the hypoglycemic activities of Exenatide.
FamotidineThe metabolism of Famotidine can be decreased when combined with Moclobemide.
FelodipineMoclobemide may increase the hypotensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fencamfamine.
FenfluramineMoclobemide may increase the serotonergic activities of Fenfluramine.
FenoldopamMoclobemide may increase the hypotensive activities of Fenoldopam.
FenoterolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fenoterol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Moclobemide.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Moclobemide.
FloxuridineThe metabolism of Moclobemide can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Moclobemide can be decreased when combined with Fluconazole.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Moclobemide.
FluorouracilThe metabolism of Moclobemide can be decreased when combined with Fluorouracil.
FluoxetineMoclobemide may increase the serotonergic activities of Fluoxetine.
FluoxetineThe metabolism of Moclobemide can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fluspirilene.
FlutamideThe metabolism of Flutamide can be decreased when combined with Moclobemide.
FluvastatinThe metabolism of Moclobemide can be decreased when combined with Fluvastatin.
FluvoxamineMoclobemide may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe metabolism of Moclobemide can be decreased when combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Moclobemide.
FosinoprilMoclobemide may increase the hypotensive activities of Fosinopril.
FosphenytoinThe metabolism of Moclobemide can be increased when combined with Fosphenytoin.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Moclobemide.
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Moclobemide.
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Moclobemide.
GemfibrozilThe metabolism of Moclobemide can be decreased when combined with Gemfibrozil.
GliclazideMoclobemide may increase the hypoglycemic activities of Gliclazide.
GlimepirideMoclobemide may increase the hypoglycemic activities of Glimepiride.
GlipizideMoclobemide may increase the hypoglycemic activities of Glipizide.
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Moclobemide.
GlyburideMoclobemide may increase the hypoglycemic activities of Glyburide.
GranisetronGranisetron may increase the serotonergic activities of Moclobemide.
GuanabenzMoclobemide may increase the hypotensive activities of Guanabenz.
GuanadrelMoclobemide may increase the hypotensive activities of Guanadrel.
GuanethidineMoclobemide may increase the hypotensive activities of Guanethidine.
GuanfacineMoclobemide may increase the hypotensive activities of Guanfacine.
HaloperidolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Haloperidol.
HaloperidolThe metabolism of Moclobemide can be decreased when combined with Haloperidol.
HexamethoniumMoclobemide may increase the hypotensive activities of Hexamethonium.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Moclobemide.
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Moclobemide.
HydralazineMoclobemide may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideMoclobemide may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Hydrocodone.
HydroflumethiazideMoclobemide may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Hydromorphone.
Hydroxyamphetamine hydrobromideMoclobemide may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Moclobemide.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Moclobemide.
IloperidoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Iloperidone.
ImatinibThe metabolism of Imatinib can be decreased when combined with Moclobemide.
ImipramineMoclobemide may increase the serotonergic activities of Imipramine.
ImipramineThe metabolism of Moclobemide can be decreased when combined with Imipramine.
IndacaterolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Indacaterol.
IndalpineMoclobemide may increase the serotonergic activities of Indalpine.
IndapamideMoclobemide may increase the hypotensive activities of Indapamide.
IndenololMoclobemide may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Moclobemide can be decreased when combined with Indinavir.
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Moclobemide.
IndoraminMoclobemide may increase the hypotensive activities of Indoramin.
Insulin AspartMoclobemide may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirMoclobemide may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineMoclobemide may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineMoclobemide may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanMoclobemide may increase the hypoglycemic activities of Insulin Human.
Insulin LisproMoclobemide may increase the hypoglycemic activities of Insulin Lispro.
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Moclobemide.
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Moclobemide.
IrbesartanMoclobemide may increase the hypotensive activities of Irbesartan.
IrbesartanThe metabolism of Moclobemide can be decreased when combined with Irbesartan.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Moclobemide.
IsoetarineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Isoetarine.
IsomethepteneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Isometheptene.
IsoniazidThe metabolism of Moclobemide can be decreased when combined with Isoniazid.
IsoprenalineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Isoprenaline.
IsradipineMoclobemide may increase the hypotensive activities of Isradipine.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Moclobemide.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Moclobemide.
KetoconazoleThe metabolism of Moclobemide can be decreased when combined with Ketoconazole.
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Moclobemide.
LabetalolMoclobemide may increase the hypotensive activities of Labetalol.
LacidipineMoclobemide may increase the hypotensive activities of Lacidipine.
LanreotideMoclobemide may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Moclobemide.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Moclobemide.
LatanoprostMoclobemide may increase the hypotensive activities of Latanoprost.
LeflunomideThe metabolism of Moclobemide can be decreased when combined with Leflunomide.
LercanidipineMoclobemide may increase the hypotensive activities of Lercanidipine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Moclobemide.
LevomilnacipranMoclobemide may increase the serotonergic activities of Levomilnacipran.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Moclobemide.
LevonordefrinMoclobemide may increase the hypertensive activities of Levonordefrin.
LinezolidThe risk or severity of adverse effects can be increased when Moclobemide is combined with Linezolid.
LiraglutideMoclobemide may increase the hypoglycemic activities of Liraglutide.
LisdexamfetamineMoclobemide may increase the hypertensive activities of Lisdexamfetamine.
LisinoprilMoclobemide may increase the hypotensive activities of Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Moclobemide.
LithiumThe risk or severity of adverse effects can be increased when Moclobemide is combined with Lithium.
LofexidineMoclobemide may increase the hypotensive activities of Lofexidine.
LopinavirThe metabolism of Moclobemide can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of Moclobemide can be decreased when combined with Lorcaserin.
LosartanMoclobemide may increase the hypotensive activities of Losartan.
LosartanThe metabolism of Moclobemide can be decreased when combined with Losartan.
LovastatinThe metabolism of Moclobemide can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Loxapine.
Lu AA21004Moclobemide may increase the serotonergic activities of Lu AA21004.
LuliconazoleThe serum concentration of Moclobemide can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Moclobemide can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Moclobemide can be decreased when combined with Lumefantrine.
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Moclobemide.
LurasidoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Lurasidone.
MacitentanMoclobemide may increase the hypotensive activities of Macitentan.
ManidipineMoclobemide may increase the hypotensive activities of Manidipine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Moclobemide.
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Moclobemide.
MecamylamineMoclobemide may increase the hypotensive activities of Mecamylamine.
MecaserminMoclobemide may increase the hypoglycemic activities of Mecasermin.
MelatoninThe metabolism of Melatonin can be decreased when combined with Moclobemide.
MelperoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Melperone.
MephentermineMoclobemide may increase the hypertensive activities of Mephentermine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Moclobemide.
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Moclobemide.
MequitazineMoclobemide may increase the anticholinergic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Mesoridazine.
MetaraminolMoclobemide may increase the hypertensive activities of Metaraminol.
MetforminMoclobemide may increase the hypoglycemic activities of Metformin.
MethadoneThe metabolism of Moclobemide can be decreased when combined with Methadone.
MethamphetamineMoclobemide may increase the hypertensive activities of Methamphetamine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Methotrimeprazine.
MethotrimeprazineThe metabolism of Moclobemide can be decreased when combined with Methotrimeprazine.
MethoxamineMoclobemide may increase the hypertensive activities of Methoxamine.
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Moclobemide.
MethyldopaThe risk or severity of adverse effects can be increased when Moclobemide is combined with Methyldopa.
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Moclobemide.
Methylene blueMoclobemide may increase the serotonergic activities of Methylene blue.
MethylphenidateMoclobemide may increase the hypertensive activities of Methylphenidate.
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Moclobemide.
MetipranololMoclobemide may increase the hypotensive activities of Metipranolol.
MetoclopramideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Metoclopramide.
MetolazoneMoclobemide may increase the hypotensive activities of Metolazone.
MetoprololMoclobemide may increase the hypotensive activities of Metoprolol.
MetoprololThe metabolism of Moclobemide can be decreased when combined with Metoprolol.
MianserinMoclobemide may increase the neurotoxic activities of Mianserin.
MibefradilMoclobemide may increase the hypotensive activities of Mibefradil.
MidodrineMoclobemide may increase the hypertensive activities of Midodrine.
MifepristoneThe serum concentration of Moclobemide can be increased when it is combined with Mifepristone.
MifepristoneMoclobemide may increase the hypoglycemic activities of Mifepristone.
MiglitolMoclobemide may increase the hypoglycemic activities of Miglitol.
MilnacipranMoclobemide may increase the serotonergic activities of Milnacipran.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Moclobemide.
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Moclobemide.
MinoxidilMoclobemide may increase the hypotensive activities of Minoxidil.
MirabegronThe metabolism of Moclobemide can be decreased when combined with Mirabegron.
MirtazapineMoclobemide may increase the central neurotoxic activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Moclobemide.
ModafinilThe metabolism of Moclobemide can be decreased when combined with Modafinil.
MoexiprilMoclobemide may increase the hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Morphine.
MoxonidineMoclobemide may increase the hypotensive activities of Moxonidine.
NadololMoclobemide may increase the hypotensive activities of Nadolol.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Moclobemide.
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Moclobemide.
NateglinideMoclobemide may increase the hypoglycemic activities of Nateglinide.
NebivololMoclobemide may increase the hypotensive activities of Nebivolol.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Moclobemide.
NelfinavirThe metabolism of Moclobemide can be decreased when combined with Nelfinavir.
NevirapineThe metabolism of Moclobemide can be decreased when combined with Nevirapine.
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Moclobemide.
NicardipineMoclobemide may increase the hypotensive activities of Nicardipine.
NicardipineThe metabolism of Moclobemide can be decreased when combined with Nicardipine.
NicorandilMoclobemide may increase the hypotensive activities of Nicorandil.
NicotineThe metabolism of Nicotine can be decreased when combined with Moclobemide.
NiguldipineMoclobemide may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Moclobemide can be decreased when combined with Nilotinib.
NilutamideThe metabolism of Nilutamide can be decreased when combined with Moclobemide.
NilvadipineMoclobemide may increase the hypotensive activities of Nilvadipine.
NimodipineMoclobemide may increase the hypotensive activities of Nimodipine.
NisoldipineMoclobemide may increase the hypotensive activities of Nisoldipine.
NitrendipineMoclobemide may increase the hypotensive activities of Nitrendipine.
NitroprussideMoclobemide may increase the hypotensive activities of Nitroprusside.
NorepinephrineMoclobemide may increase the hypertensive activities of Norepinephrine.
NortriptylineMoclobemide may increase the serotonergic activities of Nortriptyline.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Moclobemide.
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Moclobemide.
OctreotideMoclobemide may increase the hypoglycemic activities of Octreotide.
OlanzapineMoclobemide may increase the serotonergic activities of Olanzapine.
OlmesartanMoclobemide may increase the hypotensive activities of Olmesartan.
OlodaterolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Olodaterol.
OmapatrilatMoclobemide may increase the hypotensive activities of Omapatrilat.
OmeprazoleThe metabolism of Moclobemide can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Moclobemide is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Moclobemide.
OrciprenalineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Orciprenaline.
OsanetantThe risk or severity of adverse effects can be increased when Moclobemide is combined with Osanetant.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Moclobemide.
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Moclobemide.
OxprenololMoclobemide may increase the hypotensive activities of Oxprenolol.
OxycodoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Moclobemide.
PaliperidoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Paliperidone.
PalonosetronPalonosetron may increase the serotonergic activities of Moclobemide.
PanobinostatThe metabolism of Moclobemide can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Moclobemide can be decreased when combined with Pantoprazole.
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Moclobemide.
PargylineMoclobemide may increase the hypotensive activities of Pargyline.
ParoxetineMoclobemide may increase the serotonergic activities of Paroxetine.
ParoxetineThe metabolism of Moclobemide can be decreased when combined with Paroxetine.
PasireotideMoclobemide may increase the hypoglycemic activities of Pasireotide.
Peginterferon alfa-2bThe serum concentration of Moclobemide can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololMoclobemide may increase the hypotensive activities of Penbutolol.
PentamidineMoclobemide may increase the hypoglycemic activities of Pentamidine.
PentobarbitalThe metabolism of Pentobarbital can be decreased when combined with Moclobemide.
PentoliniumMoclobemide may increase the hypotensive activities of Pentolinium.
PergolideThe metabolism of Pergolide can be decreased when combined with Moclobemide.
PerindoprilMoclobemide may increase the hypotensive activities of Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Moclobemide is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Perphenazine.
PethidineMoclobemide may increase the serotonergic activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Moclobemide.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Moclobemide.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Moclobemide.
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Moclobemide.
PhenobarbitalThe metabolism of Phenobarbital can be decreased when combined with Moclobemide.
PhenoxybenzamineMoclobemide may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Moclobemide.
PhentermineMoclobemide may increase the hypertensive activities of Phentermine.
PhentolamineMoclobemide may increase the hypotensive activities of Phentolamine.
PhenylephrineMoclobemide may increase the hypertensive activities of Phenylephrine.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Phenylpropanolamine.
PhenytoinThe metabolism of Moclobemide can be increased when combined with Phenytoin.
PholcodinePholcodine may increase the serotonergic activities of Moclobemide.
PimozideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Pimozide.
PinacidilMoclobemide may increase the hypotensive activities of Pinacidil.
PindololMoclobemide may increase the hypotensive activities of Pindolol.
PioglitazoneMoclobemide may increase the hypoglycemic activities of Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Pipotiazine.
PirbuterolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Pirbuterol.
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Moclobemide.
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Moclobemide.
PizotifenMoclobemide may increase the anticholinergic activities of Pizotifen.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Moclobemide.
PolythiazideMoclobemide may increase the hypotensive activities of Polythiazide.
PramlintideMoclobemide may increase the hypoglycemic activities of Pramlintide.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Moclobemide.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Moclobemide.
PrazosinMoclobemide may increase the hypotensive activities of Prazosin.
PrimidoneThe metabolism of Primidone can be decreased when combined with Moclobemide.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Moclobemide.
ProcaterolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Procaterol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Prochlorperazine.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Moclobemide.
ProguanilThe metabolism of Proguanil can be decreased when combined with Moclobemide.
PromazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Promazine.
PromazineThe metabolism of Moclobemide can be decreased when combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Moclobemide.
PropericiazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Propericiazine.
PropofolThe metabolism of Propofol can be decreased when combined with Moclobemide.
PropranololMoclobemide may increase the hypotensive activities of Propranolol.
ProtriptylineMoclobemide may increase the serotonergic activities of Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Moclobemide.
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Moclobemide.
PyrimethamineThe metabolism of Moclobemide can be decreased when combined with Pyrimethamine.
QuazepamThe metabolism of Quazepam can be decreased when combined with Moclobemide.
QuetiapineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Quetiapine.
QuinaprilMoclobemide may increase the hypotensive activities of Quinapril.
QuinidineThe metabolism of Moclobemide can be decreased when combined with Quinidine.
QuinineMoclobemide may increase the hypoglycemic activities of Quinine.
QuinineThe metabolism of Moclobemide can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Moclobemide.
RamelteonThe metabolism of Ramelteon can be decreased when combined with Moclobemide.
RamiprilMoclobemide may increase the hypotensive activities of Ramipril.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Moclobemide.
RanolazineThe metabolism of Moclobemide can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Moclobemide.
RemikirenMoclobemide may increase the hypotensive activities of Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Remoxipride.
RepaglinideMoclobemide may increase the hypoglycemic activities of Repaglinide.
RescinnamineMoclobemide may increase the hypotensive activities of Rescinnamine.
ReserpineMoclobemide may increase the hypotensive activities of Reserpine.
RifampicinThe metabolism of Moclobemide can be increased when combined with Rifampicin.
RifapentineThe metabolism of Moclobemide can be increased when combined with Rifapentine.
RiociguatMoclobemide may increase the hypotensive activities of Riociguat.
RisperidoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Risperidone.
RitodrineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Ritodrine.
RitonavirThe metabolism of Moclobemide can be decreased when combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Moclobemide.
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Moclobemide.
RolapitantThe metabolism of Moclobemide can be decreased when combined with Rolapitant.
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Moclobemide.
RopiniroleThe metabolism of Moclobemide can be decreased when combined with Ropinirole.
RosiglitazoneMoclobemide may increase the hypoglycemic activities of Rosiglitazone.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Moclobemide.
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Moclobemide.
SalbutamolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Salbutamol.
SalmeterolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Salmeterol.
SaprisartanMoclobemide may increase the hypotensive activities of Saprisartan.
SaxagliptinMoclobemide may increase the hypoglycemic activities of Saxagliptin.
SecobarbitalThe metabolism of Moclobemide can be increased when combined with Secobarbital.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Moclobemide.
SelegilineThe metabolism of Selegiline can be decreased when combined with Moclobemide.
SelexipagMoclobemide may increase the hypotensive activities of Selexipag.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Moclobemide.
SertindoleThe risk or severity of adverse effects can be increased when Moclobemide is combined with Sertindole.
SertralineMoclobemide may increase the serotonergic activities of Sertraline.
SertralineThe metabolism of Moclobemide can be decreased when combined with Sertraline.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Moclobemide.
SitagliptinMoclobemide may increase the hypoglycemic activities of Sitagliptin.
SitaxentanMoclobemide may increase the hypotensive activities of Sitaxentan.
SorafenibThe metabolism of Moclobemide can be decreased when combined with Sorafenib.
SpiraprilMoclobemide may increase the hypotensive activities of Spirapril.
StiripentolThe metabolism of Moclobemide can be decreased when combined with Stiripentol.
SulfadiazineMoclobemide may increase the hypoglycemic activities of Sulfadiazine.
SulfadiazineThe metabolism of Moclobemide can be decreased when combined with Sulfadiazine.
SulfamethoxazoleMoclobemide may increase the hypoglycemic activities of Sulfamethoxazole.
SulfamethoxazoleThe metabolism of Moclobemide can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleMoclobemide may increase the hypoglycemic activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Moclobemide can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Moclobemide.
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Moclobemide.
SunitinibMoclobemide may increase the hypoglycemic activities of Sunitinib.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Moclobemide.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Moclobemide.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Moclobemide.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Moclobemide.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Moclobemide is combined with Tedizolid Phosphate.
TelmisartanMoclobemide may increase the hypotensive activities of Telmisartan.
TemazepamThe metabolism of Temazepam can be decreased when combined with Moclobemide.
TemocaprilMoclobemide may increase the hypotensive activities of Temocapril.
TeniposideThe metabolism of Teniposide can be decreased when combined with Moclobemide.
TerbinafineThe metabolism of Moclobemide can be decreased when combined with Terbinafine.
TerbutalineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Terbutaline.
TerlipressinMoclobemide may increase the hypotensive activities of Terlipressin.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Moclobemide.
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Moclobemide.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Moclobemide.
TetryzolineMoclobemide may increase the hypertensive activities of Tetryzoline.
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Moclobemide.
ThioproperazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Thioproperazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Moclobemide.
ThioridazineThe metabolism of Moclobemide can be decreased when combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Thiothixene.
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Moclobemide.
TianeptineMoclobemide may increase the serotonergic activities of Tianeptine.
TiboloneMoclobemide may increase the hypotensive activities of Tibolone.
TicagrelorThe metabolism of Moclobemide can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Moclobemide can be decreased when combined with Ticlopidine.
TicrynafenMoclobemide may increase the hypotensive activities of Ticrynafen.
TimololMoclobemide may increase the hypotensive activities of Timolol.
TipranavirThe metabolism of Moclobemide can be decreased when combined with Tipranavir.
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Moclobemide.
TolazamideMoclobemide may increase the hypoglycemic activities of Tolazamide.
TolazolineMoclobemide may increase the hypotensive activities of Tolazoline.
TolbutamideMoclobemide may increase the hypoglycemic activities of Tolbutamide.
TolbutamideThe metabolism of Moclobemide can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Moclobemide.
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Moclobemide.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Moclobemide.
TopiramateThe metabolism of Moclobemide can be decreased when combined with Topiramate.
TorasemideMoclobemide may increase the hypotensive activities of Torasemide.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Moclobemide.
TramadolTramadol may increase the neuroexcitatory activities of Moclobemide.
TramadolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Tramadol.
TrandolaprilMoclobemide may increase the hypotensive activities of Trandolapril.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Moclobemide.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Moclobemide.
TravoprostMoclobemide may increase the hypotensive activities of Travoprost.
TrazodoneMoclobemide may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Moclobemide.
TreprostinilMoclobemide may increase the hypotensive activities of Treprostinil.
TrichlormethiazideMoclobemide may increase the hypotensive activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Triflupromazine.
TrimazosinMoclobemide may increase the hypotensive activities of Trimazosin.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Moclobemide.
TrimethaphanMoclobemide may increase the hypotensive activities of Trimethaphan.
TrimethoprimThe metabolism of Moclobemide can be decreased when combined with Trimethoprim.
TrimipramineMoclobemide may increase the serotonergic activities of Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Moclobemide.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Moclobemide.
UnoprostoneMoclobemide may increase the hypotensive activities of Unoprostone.
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Moclobemide.
ValsartanMoclobemide may increase the hypotensive activities of Valsartan.
ValsartanThe metabolism of Moclobemide can be decreased when combined with Valsartan.
VenlafaxineThe metabolism of Moclobemide can be decreased when combined with Venlafaxine.
VenlafaxineMoclobemide may increase the serotonergic activities of Venlafaxine.
VerapamilThe metabolism of Verapamil can be decreased when combined with Moclobemide.
VilanterolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Vilanterol.
VilazodoneMoclobemide may increase the serotonergic activities of Vilazodone.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Moclobemide.
VoriconazoleThe metabolism of Moclobemide can be decreased when combined with Voriconazole.
VortioxetineMoclobemide may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Moclobemide.
WarfarinThe metabolism of Warfarin can be decreased when combined with Moclobemide.
XylometazolineMoclobemide may increase the hypotensive activities of Xylometazoline.
ZafirlukastThe metabolism of Moclobemide can be decreased when combined with Zafirlukast.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Moclobemide.
ZimelidineMoclobemide may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Ziprasidone.
ZiprasidoneThe metabolism of Moclobemide can be decreased when combined with Ziprasidone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Moclobemide.
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Moclobemide.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Moclobemide.
ZotepineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Zuclopenthixol.
Food Interactions
  • Food slows absorption a little. Avoid alcohol. Take after meals in order to minimize the risk of interaction with tyramine.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Berlin I, Zimmer R, Thiede HM, Payan C, Hergueta T, Robin L, Puech AJ: Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Br J Clin Pharmacol. 1990 Dec;30(6):805-16. [PubMed:1705137 ]
  3. Fulton B, Benfield P: Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs. 1996 Sep;52(3):450-74. [PubMed:8875133 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Fisar Z, Hroudova J, Raboch J: Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. Neuro Endocrinol Lett. 2010;31(5):645-56. [PubMed:21200377 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23